MyChesCo on MSN40m
Johnson & Johnson Highlights Promising Data on Investigational Autoantibody Drug Nipocalimab
Johnson & Johnson has unveiled groundbreaking findings on nipocalimab, an investigational FcRn blocker, in a recent ...
ksn.com2h
Ellsworth woman raising awareness to rare neuromuscular disease
ELLSWORTH, Kan. (KSNW) – A woman from Ellsworth is navigating life with a rare neuromuscular disease. Tina Bruning learned of her diagnosis of Generalized Myasthenia Gravis, or gMG, in May 2021.
The American Journal of Managed Care3d
Nipocalimab’s Promising Potential in Advancing gMG Care
For part 3 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the favorable safety ...
Immunovant price target lowered to $38 from $45 at BofA
BofA analyst Jason Gerberry lowered the firm’s price target on Immunovant (IMVT) to $38 from $45 and keeps a Buy rating on the shares. The firm ...